Open access peer-reviewed chapter

Mediators of Impaired Adipogenesis in Obesity-Associated Insulin Resistance and T2DM

By Haya Al-Sulaiti, Alexander S. Dömling and Mohamed A. Elrayess

Submitted: May 13th 2019Reviewed: July 22nd 2019Published: August 28th 2019

DOI: 10.5772/intechopen.88746

Downloaded: 84


Obesity has become a global health issue due to its high prevalence and associated comorbidities including insulin resistance (IR) and type 2 diabetes mellitus (T2DM). Obesity is associated with the expansion of adipose tissues through hypertrophy of mature adipocytes and differentiation of local preadipocytes in a process known as adipogenesis to store excess triacylglycerols (TAGs). Impairment of adipogenesis leads to ectopic fat deposition in skeletal muscles, liver, and kidneys, triggering IR in these tissues and increased risk of T2DM. Many factors contribute to impaired adipogenesis including obesity-associated mild chronic inflammation, oxidative stress, and fatty acid signaling. This review summarizes recent literature covering mediators of impaired adipogenesis and underlying molecular pathways.


  • adipogenesis
  • mediators
  • inflammation
  • oxidative stress
  • fatty acids

1. Obesity-associated metabolic disease

Rapidly changing lifestyle, accompanied by consumption of excess energy in the form of a calorie-rich high-fat diet, lower voluntary activity, and increased exposure to environmental pollutants, have led to an exponential rise in noncommunicable metabolic diseases [1]. A key component of chronic metabolic diseases is obesity that has become a global health problem associated with a range of comorbidities including insulin resistance and type 2 T2DM [2], coronary artery disease (CAD) [3], nonalcoholic fatty liver [4], cancers [5], and elevated risk of premature death [6, 7].

Adipose tissue is an endocrine organ that responds to obesity by secreting elevated quantities of free fatty acids, adipokines, and proinflammatory cytokines, triggering IR and risk of T2DM [8]. Obesity is also characterized by increased adiposity mediated by enlarged size of mature adipocytes (hypertrophy) and elevated number of newly recruited adipocytes (hyperplasia) [9, 10, 11, 12]. Adipose tissue dysfunction is characterized by adipocyte hypertrophy, mild chronic inflammation, and oxidative stress, causing reduced ability to generate new adipocytes from the undifferentiated precursors (preadipocytes). The impaired adipogenesis increases risk of IR and T2DM by triggering ectopic fat deposition in nonadipose tissues and proinflammatory environment characterized by impaired secretion of various adipose-derived adipokines [13].

Obesity also represents an imbalance between the primary site of storing energy (the white fat) and the site that is specialized in energy expenditure (the brown fat) [14]. White adipocytes store fat in the form of triacylglycerols as a single fat lipid droplet that gets readily hydrolyzed by lipases when energy is needed. The resulting fatty acids are mobilized to other tissues to undergo fatty acid oxidation as a source of energy [15]. The imbalance between lipolysis and lipogenesis plays a crucial role in progression of metabolic disease including T2DM and nonalcoholic fatty liver disease [16]. The brown fat, on the other hand, uses the energy derived from fatty acid oxidation for heat generation [17].

Adipocyte hypertrophy is associated with increased uptake of excess TAGs, which triggers fat accumulation within the larger subcutaneous adipose tissue (SAT) [18, 19, 20]. SAT therefore plays a buffering role as it prohibits progression of obesity-associated pathologies [21]. However, the buffering capacity becomes limited as impairment of SAT expansion causes IR [22, 23, 24] as the excess fat are deposited in the visceral adipose tissue (VAT) as well as ectopically in the skeletal muscle, liver, kidney, and heart tissues [25]. This is augmented by the infiltration of macrophages and activation of the innate immune cells [26], which triggers hyperinsulinemia that inhibits lipolysis and activates lipoprotein lipase (LPL). This causes further hyperinsulinemia, hypertriglyceridemia, increased IR in these tissues [27], and risk of T2DM [28].

Although obesity is generally associated with these comorbidities, some obese individuals seem to be protected as they maintain insulin sensitivity (IS) and show lower hypertension and proatherogenic and inflammatory profiles than their equally obese pathogenic counterparts [29, 30, 31, 32]. Investigating the underlying causes for this protective phenotype could potentially help obesity-associated pathogenicity. Although still unknown, various potential mechanisms were proposed to contribute to metabolically healthy obese (MHO) phenotype. These include lower visceral and ectopic fat deposition than subcutaneous fat accumulation due to efficient SAT adipogenesis, reduced inflammatory component in the adipose tissue, healthy levels of secreted adipokines, and more active lifestyle [33]. A genetic component was also suggested to interact with various environmental factors, although not yet determined [34]. Interestingly, lean diabetics also exhibit larger adipocytes than healthy individuals, perhaps due to impaired differentiation of preadipocytes but not a result of different frequencies of stromal vascular cells, lipolysis, or levels of inflammatory mediators [35]. Current therapeutic strategies focus on treating obesity-associated diseases instead of preventing the underlying mechanisms. Therefore, understanding the molecular mediators underlying the protective phenotype in MHO individuals could provide critical information to help individuals suffering from pathological obesity (PO). In this review, we aimed to understand the role of adipogenesis in obesity-associated IR and T2DM by screening 2317 articles investigating adipogenesis and mediators of impaired adipogenesis in PubMed with the aid of Rayyne, a systematic review web application [36].

2. The role of adipogenesis in obesity-associated IR and T2DM

The adipose tissue is a dynamic part of the endocrine system that plays a crucial role in maintaining energy balance and nutritional homeostasis [37]. Mature adipocytes constitute the most abundant distinctive cell type in the adipose tissue, occupying 90% of its volume [38]. Other components include leukocytes, macrophages, fibroblasts, endothelial cells, and preadipocytes, which constitute the stromal vascular cells (4–6 million cells per gram of adipose tissue, half of which are immune cells) [39].

Obesity-induced adipocyte hypertrophy is associated with impaired recruitment and differentiation of preadipocytes. Despite their abundance, preadipocytes fail to undergo terminal differentiation into mature adipocytes via the activation of the canonical Wnt signaling [40]. Preadipocytes are produced by mesenchymal stem cells (MSCs) under the influence of different signaling molecules. The mature adipocytes secrete BMP4 that triggers preadipocyte differentiation by inducing the separation of Wnt1 inducible-signaling pathway protein 2 (WISP2) and zinc finger protein 423 (ZNF423), allowing ZNF423 to translocate into the nucleus and activate peroxisome proliferator-activated receptors (PPARγ) and downstream cascade including CCAAT/enhancer-binding proteins β (C/EBPβ), δ, and α [41, 42] ( Figure 1 ).

Figure 1.

Schematic representation of the role of Wnt signaling in adipogenesis.

BMP4 also plays an anti-inflammatory role by reducing tumor necrosis factor-α (TNF-α)-mediated proinflammatory cytokine induction in human adipocytes. Therefore, BMP4 plays a protective role against IR and T2DM [43]. Subsequently, PPARγ and C/EBPα activate preadipocyte differentiation and the expression of mature makers such as adiponectin, fatty acid-binding protein 4 (FABP4), glucose transporter type 4 (GLUT4), and LPL. The activation of PPARγ, therefore, maintains IS and exhibits an anti-inflammatory function, whereas IR causes impaired adipogenesis and increased risk of T2DM [44, 45].

Insulin and downstream Akt signaling also play important roles as modulators of adipose tissue growth and adipogenesis as insulin activates glucose and free fatty acid uptake, inhibits lipolysis, and de novo fatty acid synthesis in adipocytes, and induces adipogenesis [46]. The transcription factor nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) has been shown to induce energy expenditure and reduce adipose tissue growth, leading to prevention of dietary obesity and lowering adipogenesis, inflammation, and IR [47]. The inhibition of inhibitor of nuclear factor kappa-B kinase subunit β (IKKβ) in mice lowers high-fat diet-induced adipogenesis and inflammation and protects from diet-induced obesity and IR [48]. MicroRNAs (miRNAs) have been also shown to play an important role in adipogenesis, IR, and inflammation as previously reviewed [49].Tonicity-responsive enhancer-binding protein (TonEBP), a key transcription factor involved in cellular adaptation to hypertonic stress, has been suggested to influence macrophage activity, adipogenesis, and IS by inhibiting the epigenetic transition of PPARγ2 [50]. Protectin DX (PDX), a ω-3 fatty acid-derived proresolution mediator, was reported to reduce inflammation and IR via an AMPK-dependent pathway and suppress adipogenesis and lipid accumulation during 3T3-L1 differentiation [51].

We have recently shown that higher adipogenic capacity of preadipocytes isolated from SAT and VAT from MHO individuals than PO counterparts may be one of the underlying mechanisms for MHO protection due to a greater ability to store TAGs in the SAT depot. This process was shown to be influenced by inflammatory mediators, oxidative stress, and fatty acid signaling [45, 52, 53, 54, 55].

3. Mediators of impaired adipogenesis in IR and T2DM

3.1 Inflammatory mediators

3.1.1 Impaired adipogenesis in response to proinflammatory signals

Obesity-associated comorbidities are mediated by chronic mild inflammation ( Figure 2 ). Lipid-laden adipocytes produce increased levels of cytokines such as Interleukin 6 (IL-6), IL-β, TNF-α, monocyte chemoattractant protein-1 (MCP-1), and IL-8 [10, 56, 57] which can inhibit preadipocyte differentiation [21, 45]. The impaired adipogenesis is associated with stress of the endoplasmic reticulum (ER) and elevated expression of unfolded protein response (UPR), both can exacerbate the proinflammatory phenotype of preadipocytes and adipocytes [58]. The effect of proinflammatory phenotype varies among various fat depots. VAT is a more inflammatory tissue than SAT as it secretes higher levels of proinflammatory cytokines. Macrophage infiltration into adipose tissue is regulated through serum resistin and leptin in obese individuals with early metabolic dysfunction [59]. The presence of macrophages in VAT contributes significantly to this phonotype. The presence of macrophages in human SAT, on the other hand, is causally related to impaired preadipocyte differentiation, which in turn is associated with systemic IR [60, 61]. Adipocyte differentiation, therefore, was shown to be significantly lower in VAT than SAT. Macrophage depletion can reduce inflammatory cytokines and trigger adiponectin secretion from both SAT and VAT adipocytes, leading to the induction of preadipocyte differentiation in SAT, but not VAT. Additionally, a negative correlation between SAT adipogenesis, but not VAT, and systemic IR was observed [62]. Chronic systemic inflammation is also associated with elevated lipolysis in white adipose tissue and lipogenesis in nonadipose tissues, causing ectopic fat deposition in nonadipose tissues and imbalance in free fatty acid homeostasis and increased risk of IR [63].

Figure 2.

Mediators of impaired adipogenesis in IR and T2DM. Most proinflammatory cytokines as well as some anti-inflammatory mediators can impair adipogenesis (1). Similarly, various mediators of oxidative stress can impact adipogenesis both positively and negatively depending on their structure (2). Fatty acid signaling plays a key role in adipogenesis but at various degrees depending on the composition of the fatty acids (3). Finally, various environmental factors can impact adipogenesis mostly negatively (4).

Among the proinflammatory cytokines, IL-6 is produced by adipocytes, activated leukocytes, and endothelial cells [64] in obesity [65, 66, 67, 68]. IL-6 shows a synergistic effect with other mediators of metabolic disease, collectively contributing to the progression of other obesity-associated comorbidities such as CAD and T2DM [64, 69]. IL-6 impairs the LPL function leading to increased levels of circulating fat [69, 70]. Moreover, obesity-associated increase in IL-6 is linked to reduced insulin-triggered glucose uptake [60, 61]. Previous reports have indicated that insulin treatment improves the glucose transport activity of adipocytes in T2DM [21] and lowers IL-6 and TNF-α levels [53]. Although the precise mechanisms of IL-6-associated IR is not well characterized, human adipocytes from IR individuals were shown to exhibit significantly higher IL-6 expression levels [45]. IL-6 impairs insulin action by inhibiting expression of insulin receptor, insulin receptor substrate-1 (IRS-1), and GLUT4 in human preadipocytes as well as 3T3-L1 adipocytes [45, 71]. Furthermore, IL-6 was shown to reduce IS through decrease in adiponectin expression and secretion [72] and via impairment of insulin signaling in hepatocytes [73].

Various other cytokines have been shown to impact adipogenesis [74]. The proinflammatory cytokines IL-1 β, TNF-α, and MCP1 can also influence the hyperplastic expansion of adipose tissue and impair adipogenesis [59]. IL-1β triggers a proinflammatory response in human adipose tissues, particularly in VAT depot. IL-1β also inhibits insulin signal transduction, leading to impaired IS in adipose tissue [75]. IL-1β and cyclooxygenase-2 (COX-2) play a detrimental role in adipose tissue dysfunction in obesity [76]. With obesity, levels of MCP-1 and TNF-α increase in VAT before macrophage infiltration, suggesting a highly proinflammatory phenotype of the visceral depot prior to infiltration of immune cells and macrophage phenotype switch [77]. Unlike IL-6, IL-1 β, and TNF-α, MCP-1 and MCP-1-induced protein (MCPIP) were shown to induce adipogenesis. Treatment of reactive oxygen species (ROS) inhibitor, apocynin, reduced the MCPIP-triggered adipogenesis [78]. Other cytokines involved in adipogenesis include interferon-γ (IFN-γ), a central mediator of macrophage function. Compared to obese wild-type control animals, obese IFN-γ knockouts exhibit better IS, smaller adipocyte size, and lower cytokine expression [79].

3.1.2 Impaired adipogenesis in response to anti-inflammatory signals

Contrary to the notion that inflammation plays a negative role in metabolism, some studies suggest that proinflammatory signals in the adipocytes are actually needed for functional adipose tissue homeostasis ( Figure 2 ). Indeed, adipose tissue inflammation was shown in various animal models of adipose tissue-specific reduction of proinflammatory potential to be required as an adaptive response, allowing proper storage of excess fat and filtering of gut-derived endotoxins [80]. Additionally, various molecules with anti-inflammatory properties were shown to influence adipogenesis and risk of IR. Myokines, for example, secreted by skeletal muscle cells during exercise such as β-aminoisobutyric acid, can impair adipogenesis via activating AMPK signaling pathway and reducing levels of proinflammatory cytokines such as TNF-α [81]. Another example is the ubiquitin-editing enzyme A20 that impairs IL-6 secretion from adipocytes, leading to modulation of differentiation of MSCs [82]. The overexpression of A20 was also shown to reduce lipogenesis and adipogenesis via lowering levels of sterol regulatory element binding protein-1c (SREBP-1c) and aP2, causing lower fat accumulation in differentiated 3T3-L1 cells [83]. A third example is the nonerythropoietic EPO-derived peptide that plays an anti-inflammatory and anti-adipogenic roles in high-fat die mice with IR [84]. On the other hand, other anti-inflammatory molecules could rescue impaired adipogenesis. Glucose-dependent insulinotropic polypeptide (GIP), for example, is a potent activator of adipogenesis through modulation of inflammation in adipose tissue [85]. Additionally, the expression of neuronatin (Nnat), a proteolipid involved in neuronal development, in response to inflammation and dietary excess, has been suggested to play an important role in adipogenesis through lowering oxidative stress and inflammation [86].

3.2 Oxidative stress

Obesity leads to the accumulation of ROS, the hallmark of oxidative stress, in the adipose tissue causing impaired adipogenesis and increased risk of IR and T2DM. The balance between ROS generation and activation of endogenous antioxidants is crucial for cells undergoing adipogenesis [87] ( Figure 2 ). The oxidative damage and changes in the expression of antioxidant enzymes with age are similar between SAT and VAT. However, preadipocytes from SAT are significantly more resistant than VAT-derived cells to cell death caused by oxidative stress [88]. Interestingly, within SAT and VAT depots, preadipocytes from insulin-sensitive obese subjects were more prone to oxidative damage than preadipocytes from equally obese insulin-resistant individuals [52, 53]. The depletion of ROS from adipose tissue in mice models of oxidative stress was associated with increased adipose tissue mass, lower ectopic fat deposition, and enhanced IS. Similarly, ROS accumulation limited the expansion of adipose tissue, leading to elevated ectopic fat accumulation and increased risk of IR [89]. Elevated ROS within the adipose tissue triggers lipid peroxidation [45] and accumulation of reactive aldehydes including the bioactive lipid peroxidation product 4-hydroxynonenal (4-HNE) [90]. Elevated 4-HNE causes damage of cell structure and function through the formation of the stable adducts 4-hydroxyalkenals with proteins, phospholipids, and DNA [91, 92]. Increased 4-HNE levels have been associated with impaired adipogenesis and IR [53, 93, 94, 95, 96]. Another marker of oxidative damage is 8-hydroxy-2-deoxyguanosine (8-OHdG) which was recently shown to exert anti-inflammatory effects, by reducing TNF-α-induced IR in vitro. It was also shown to reduce adipose tissue mass in vivo through activation of adipose triglyceride lipase and lowering the expression of fatty acid synthase [97]. Levels of cholesterol oxidation-derived oxysterols increase in adipose tissues of T2DM patients and act as inhibitors of adipogenesis through activation of Wnt pathway [98]. Heme oxygenase (HO), a major cytoprotective enzyme, functions upstream of Wnt signaling and lowers lipogenesis and adipogenesis, decreasing lipid accumulation and levels of proinflammatory cytokines [99].

Conversely, ROS was also shown to enhance adipogenesis by lowering sirtuin 1 (Sirt1) expression [100, 101]. Heme-induced oxidative stress was shown to inhibit Sirt1, leading to increased adipogenesis [102]. The expression of deleted in bladder cancer protein 1 (DBC1), another inhibitor of the Sirt1, is reduced with obesity, leading to lower adipogenesis and VAT dysfunction [103]. Sirt3 plays a crucial role in mitochondrial function. Silencing of Sirt3 can cause adipocyte dysfunction which impairs adipogenesis and causes IR [104]. Nonselenocysteine-containing phospholipid hydroperoxide glutathione peroxidase (NPGPx) is a sensor of oxidative stress. Lack of NPGPx causes elevation in ROS and promotion of adipogenesis through ROS-dependent dimerization of protein kinase A regulatory subunits and activation of C/EBPβ [105]. Additional evidence suggesting ROS involvement in promotion of adipogenesis comes from antioxidant supplementation experiments where lower levels of ROS resulting from antioxidants contribute to adipose tissue dysfunction and IR [106]. Indeed, antioxidant supplementation exhibited a negative impact when used before induction of oxidative stress as a result of lowering physiological ROS levels because ROS plays a role as second messengers in adipogenesis, lipid metabolism, and insulin signaling [107]. For example, the supplementation with N-acetylcysteine, a known antioxidant and precursor of glutathione, was shown to reduce fat deposition during adipogenic differentiation of mouse fibroblasts [108]. Activation of beta-3 adrenergic receptor (β3-AR) enhances ROS accumulation in cultured adipocytes. Antioxidants enhance β3-AR-triggered mitochondrial ROS production, suggesting that chronic supplementation of antioxidants could indeed generate an elevation in oxidative stress associated with mitochondrial dysfunction in adipocyte [109]. On the other hand, glutathione depletion was shown to inhibit adipogenesis as the result of lowering cell proliferation during the initial mitotic clonal expansion of the adipocyte differentiation process [110].

3.3 Fatty acid signaling

The main role of adipocytes is TAG storage. Although TAGs do not function as signaling molecules per se, the lipid intermediates generated during lipogenesis and lipolysis influence intracellular insulin signaling and participate in progression of IR. These include free fatty acids, diacylglycerols (DAGs), and ceramides [111].

Lipolysis-driven efflux of fatty acids triggers TAG synthesis and causes stress of the ER and activation of June kinase pathway in the adipose tissues [112, 113]. This leads to an elevation in the levels of both DAGs and ceramides and progression of IR in adipocytes [114]. Ceramides were shown to influence lipid-mediated IR in muscles. Delta 4-desaturase, sphingolipid 1 (DEGS1) is a desaturase that mediates ceramide biosynthetic pathway. Ablation of DEGS1 in preadipocytes prevented adipogenesis and decreased lipid accumulation [115]. There are essential enzymes responsible for TAG hydrolysis including hormone-sensitive lipase (HSL), adipose triglyceride lipase (ATGL), and monoglyceride lipase (MGL) [116]. ATGL regulates lipolysis by transcription factor specificity protein 1 (Sp1). Insulin-mediated transcription of Sp1 is critical for this regulation. In mature adipocytes, PPARγ reverses transcriptional repression by Sp1 at the ATGL promoter, leading to stimulation of ATGL mRNA expression. During obesity and IR, the transcription of ATGL becomes downregulated. The extent of the downregulation depends on interactions between Sp1 and PPARγ [117].

A number of factors influence the function of fatty acids in regulating adipogenesis. The number of carbons and the position and number of double bounds are crucial determinants of properties of the fatty acids. Changes in fatty acids including elongation, desaturation, β-oxidation, peroxidation, and incorporation into phospo- and complex lipids can play an essential role in their metabolic function. Fatty acids and their metabolites can control protein expression involved in lipid and energy metabolism by influencing gene transcription, mRNA processing, and posttranslational modifications [118, 119, 120, 121]. Most fatty acids activate all three members of the PPAR family [122, 123, 124, 125]. Polyunsaturated fatty acids (PUFAs), except for erucic acid, are more potent stimulators of PPARγ than monounsaturated fatty acids (MUFAs) and saturated fatty acids [122, 123, 124, 125, 126] ( Figure 2 ). The optimal binding affinity is reached with 16–20 carbon-containing compounds. DHA too was shown to stimulate PPARs [124]. Various studies have reported the beneficial effects of PUFAs on lipid-related human disorders [127, 128, 129, 130, 131], which largely depend on the structure of the fatty acids and their metabolic properties. PUFAs can inhibit lipogenic gene transcription by downregulating the expression SREBPs [132, 133, 134, 135] and act as antagonists of liver X receptors (LXR) [136, 137] and as agonists for PPARs [122, 123, 124, 138, 139]. PUFAs, but not saturated or MUFAs, inhibit lipogenic genes by downregulating SREBP-1c. PPAR alpha plays an important role in metabolic adaptation to fasting by enhancing mitochondrial and peroxisomal fatty acid oxidation and ketogenesis [140]. Dietary PUFAs were also shown to stimulate expression of PPARα target genes, induce β-oxidation, and lower plasma TAGs [141, 142, 143, 144, 145, 146, 147, 148, 149]. Fatty acids can also play a role as modulators of kinase signaling pathways [150, 151, 152, 153, 154, 155].

Arachidonic acid (AA), a polyunsaturated omega-6 fatty acid, is the major PUFA that has been implicated in the regulation of adipogenesis. Short exposure of 3T3-L1 mouse preadipocytes to AA triggers adipocyte differentiation, associated with increase in (FABP4/aP2). Calcium, protein kinase C, and ERK play critical role in this pathway through which AA induces the expression of adipocyte protein 2 (aP2) [156]. AA binds to PPAR-γ2 to stimulate GLUT4 expression in HepG2 cell line, exhibiting an alternative insulin-independent activation of GLUT4 [157]. AA cascade is then controlled by cyclooxygenases enzymes, lipoxygenases, and P450 epoxygenases. When AA is generated from plasma membrane via phospholipases and then metabolized by prostaglandin G/H synthase, different prostaglandins are produced, causing opposing effects on adipocyte differentiation. The proadipogenic effect of AA is mediated by prostaglandin product (prostacyclin) and is thus cyclooxygenase dependent [158, 159, 160]. Among prostaglandin classes, 15-deoxy-Δ12,14-prostaglandin J2 (15-d-PGJ2) was shown to be proadipogenic [161, 162]. On the other hand, prostaglandin F2α (PGF2α) was shown to exert anti-adipogenic effects in primary preadipocytes [163, 164, 165], 1246 cells [164], and 3T3-L1 cells [166, 167, 168]. The anti-adipogenic effect of PGF2α is mediated through prostaglandin F receptor-mediated elevation in intracellular calcium and DNA synthesis [168] and activation of MAPK, causing reduction in PPARγ phosphorylation [169]. The role of prostaglandin E2 (PGE2), the third main prostaglandin, in adipogenesis is controversial as PGE2 exhibits antilipolytic effect in mature adipocytes but shows no effect on preadipocytes [170]. However, it was recently demonstrated that PGE2 inhibited adipogenesis of 3T3-L1 cells [171, 172]. Epoxyeicosatrienoic acids (EETs), AA metabolites, and AA-derived cytochrome P450 (CYP) epoxygenase metabolites exert anti-inflammatory effects in the vasculature. The expression of CYP2J, a member of P450 subfamily with a role in the bioactivation of AA in extrahepatic tissues, inhibits NF-κB and MAPK signaling pathways and activates of PPARγ, thus reducing IR and diabetic phenotype [173]. n-3 PUFAs, on the other hand, reduce adipose growth and play a role in adipogenesis in various rodent studies [174, 175, 176, 177, 178, 179, 180, 181, 182, 183].

Medium-chain fatty acids (MCFAs) (C8–C10) bind the PPARγ ligand binding domain in vitro, causing full inhibition of phosphorylation of PPARγ by cyclin-dependent kinase 5 (cdk5) and reversal of IR in adipose tissue. MCFAs that bind PPARγ also inhibit thiazolidinedione-dependent adipogenesis in vitro [184]. On the other hand, MUFAs were shown to induce adipogenesis and enhance TAG accumulation in 3T3-L1 mouse preadipocytes. Levels of TAGs were greater in cells treated with c-22:1 than c18:1 and c-20:1. Among the c-22:1 fatty acids, c9–22:1 treatment showed higher fat accumulation, associated with increased expression of adipogenic and lipogenic transcription factors, such as PPARγ and C/EBPα and SREBP-1. However, c-20:1 FAs exhibited less effect than c-18:1 and c-22:1 [185]. Alpha-lipoic acid (ALA) activates insulin signaling pathway and exerts insulin-like properties in adipose and muscle cells. However, 3T3-L1 preadipocytes treated with LA exhibit lower insulin-induced differentiation by modulating activity and/or expression of various anti-adipogenic transcription factors mainly through activating the MAPK pathways that negatively regulate PPARγ and C/EBPα [141]. 10-oxo-12(Z)-octadecenoic acid, a linoleic acid metabolite, triggered adipocyte differentiation through PPARγ activation and elevated adiponectin secretion and insulin-triggered glucose uptake [142]. Dietary n-3 fatty acids showed more effective activation of PPARα in the liver of rodents [143, 144, 145] than n-6 fatty acids [146]. Figure 3 summarizes the effect of various fatty acid species on the proadipogenic capacity of 3T3L-1 cells in the presence or absence of insulin (Madsen et al.) [147].

Figure 3.

Adipogenic capacity of various fatty acids in 3T3L-1 cells in the absence or presence of 1 μg/ml insulin in differentiation medium (MDI) containing 0.5 mM isobutyl-1-methylxanthine and 1 μM dexamethasone in DMEM and 10% FBS. 100 μM palmitic acid (palm), oleic acid (ole), erucic acid, linoleic acid (LA), arachidonic acid (AA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), or 1 μM rosiglitazone (rosi) dissolved in DMSO were added when differentiation was induced at day 0 and were present throughout the differentiation period (adapted from Madsen et al.) [147].

Lipidomics studies were performed to investigate differences between SAT and VAT depots. These studies have shown evidence of depot-specific enrichment of certain species of TAGs, glycerophospholipids, and sphingolipids and specific correlations between certain lipid species and body mass index, inflammation, and IS [148, 149]. We have recently shown in human SAT and omental (OM) adipose tissue biopsies from 64 obese individuals a number of TAGs that changed with increased risk IR and T2DM including C46:4, C48:5, C48:4, C38:1, C50:3, C40:2, C56:3, C56:4, C56:7, and C58:7. Enrichment analysis showed C12:0 fatty acid to be associated with TAGs that are least abundant in T2DM. Our data also indicated that C18:3 was present in both depleted and enriched TAGs in T2DM [55]. Secretion of interleukin IL-6 was found to be significantly lower after treatment with C18:2, C22:6, and C16:0 through blocking NF-κB and activating PPARγ [186]. Our data also showed positive correlations between C56:4 and C57:4, both containing C18:2 and C16:0, with SC adipogenic capacity. OM adipogenic capacity was associated with C49:1, C38:0, and C56:2, containing C16:0, C18:1, and C14:0 [55]. Table 1 summarizes a list of TAGs associated with SAT and OM adipogenic capacity. These fatty acids were reported to stimulate adipogenesis in rodents [187, 188, 189, 190, 191] and potentially in human preadipocytes.

Metabolic traitR 2ImportanceTAGMWFatty acid compositionFatty acid identities
SC adipogenic0.90.16C58:10926.8C18:2, C18:2, C22:6Linoleic acid, linoleic acid, docosahexaenoic acid
0.16C56:4910.8C18:1, C18:2, C20:1Oleic acid, linoleic acid, gadoleic acid
0.14C57:4924.7C22:0, C19:4, C16:0Behenic acid, C19:4, palmitic acid
0.09C40:1692.7C18:1, C16:0, C6:0Oleic acid, palmitic acid, caproic acid
0.08C60:1970.8C24:0, C24:0, C18:1Lignoceric acid, oleic acid
0.22C38:1664.7C18:1, C16:0, C4:0Oleic acid, palmitic acid, butyric acid
OM adipogenic10.18C48:1804.8C18:0, C16:1, C14:0Stearic acid, palmitoleic acid, myristic acid
0.14C49:1818.7C18:1, C17:0, C14:0Oleic acid, heptadecanoic acid, myristic acid
0.11C56:1916.8C18:0, C18:0, C20:1Stearic acid, stearic acid, gadoleic
0.09C54:0890.8C18:0, C18:0, C18:0Stearic acid, stearic acid
0.06C38:0666.7C10:0, C14:0, C14:0Capric acid, myristic acid
0.05C56:2914.8C18:1, C18:1, C20:0Oleic acid, oleic acid, arachidic acid
0.04C51:1846.7C18:1, C15:0, C18:0Oleic acid, pentadecanoic acid, stearic acid

Table 1.

List of TAGs associated with IR, SC, and OM adipogenic capacity.

4. Environmental factors

Various types of environmental factors were shown to influence adipogenesis. These include environmental pollutants. Among the environmental pollutants, polybrominated diphenyl ethers (PBDEs) represent a widely used type of flame retardants in commercial products and a main source of environmental contaminants. PBDEs accumulate in adipose tissue, potentially changing its endocrine function causing elevation in the risk of IR. We have previously shown that specific congeners of PBDEs (28, 47, 99, and 153) were predominant in VAT from obese individuals and that PBDEs 99, 28, and 47 were elevated in obese IR compared to obese IS. Treatment of human VAT-derived preadipocytes from obese IS individuals with PBDE28 inhibited insulin signaling and reduced adipogenesis [54]. In addition to PBDEs, evidence linking accumulation of other persistent organic pollutants (POPs) and risk of IR and T2DM was previously described [54, 192]. Additionally, the association between inorganic arsenic exposure and the risk of T2DM and obesity was previously reported [193]. Arsenic-induced T2DM is suggested to be mediated by inflammation, oxidative stress, and apoptosis, playing a significant role in the pathogenesis of obesity. Arsenic inhibits adipogenesis and enhances lipolysis, leading to obesity. Other reports have suggested that arsenic may induce lipodystrophy [193]. Another evidence suggests that uremic toxin-treated 3T3-L1 cells and MSC-derived adipocytes exhibit impaired adipogenesis and apoptosis through activation of the Na/K-ATPase/ROS amplification cycle [194]. Other types of environmental pollutants include organotins, widely used antifouling biocides for ships and fishing nets, play a role as endocrine disruptors as they bind to PPARγ/RXRα, induce adipogenesis, and repress inflammatory genes in different mammalian cells [195].

5. Conclusion

The pathology of obesity-associated IR and T2DM involves ectopic fat deposition in response to elevated energy intake and poor fat storage. The latter is due to impaired adipogenesis as newly recruited preadipocytes become unable to differentiate into fully functional adipocytes. This review presents several factors that influence adipogenesis in pathological obesity including inflammatory mediators, oxidative stress, fatty acid signaling, and other environmental factors. Most proinflammatory cytokines such as IL-6, IL-1β, TNF-α, IL-8, and IFNγ as well as some anti-inflammatory mediators including β-aminoisobutyric acid, A20 enzyme, and EPO have been shown to impair adipogenesis, leading to adipocyte hypertrophy, ectopic fat accumulation, and increased risk of IR and T2DM. However, basal level of adipose tissue inflammation has been shown to be required for normal adipogenesis and functional adipose tissue homeostasis. Similarly, various mediators of oxidative stress were shown to impact adipogenesis positively such as lipid peroxidation product 4-HNE and negatively such as the marker of oxidative damage 8-OHdG. Targeting lipid peroxidation products was shown to reverse impairment of adipogenesis and sustain IS. However, complete depletion of oxidative stress could also lead to impairment of adipogenesis as basal oxidative stress was shown to be required for normal adipogenesis. Fatty acid signaling also plays a very important role in adipogenesis as various fatty acid species such as PUFAs, MUFAs, and MCFAs were shown to regulate preadipocyte differentiation at various degrees depending on their composition. Finally, various environmental factors were suggested to impact adipogenesis, mainly through triggering inflammation and oxidative stress, leading to impairment of adipogenesis and increased risk of IR.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

All authors participated in reviewing the literature and preparing and approving the manuscript. MAE is responsible for the integrity of the work as a whole.


15-d-PGJ215-deoxy-Δ12,14-prostaglandin J2
AAarachidonic acid
ATGLadipose triglyceride lipase
BMP4bone morphogenetic protein 4
C/EBPCCAAT/enhancer-binding protein
CADCoronary artery disease
cdk5cyclin-dependent kinase 5
DBC1deleted in bladder cancer protein 1
DHAdocosahexaenoic acid
DMSOdimethyl sulfoxide
EETsepoxyeicosatrienoic acids
EPAeicosapentaenoic acid
EPOnonerythropoietic derived peptide
ERendoplasmic reticulum
FABP4fatty acid-binding protein 4
GIPglucose-dependent insulinotropic polypeptide
HSLhormone-sensitive lipase
IKKβinhibitor of nuclear factor kappa-B kinase subunit β
IL-6interleukin 6
IRinsulin resistance
ISinsulin sensitive
LAlinoleic acid
LPLlipoprotein lipase
LXRliver X receptors
MCFAsmedium chain fatty acids
MCP-1monocyte chemoattractant protein-1
MCPIPMcp-1-induced protein
MDIinsulin in differentiation medium
MGLmonoglyceride lipase
MHOmetabolically healthy obese
MUFAsmonounsaturated fatty acids
NF-kappa-Bnuclear factor kappa-light-chain enhancer of activated B cells
NPGPxnonselenocysteine-containing phospholipid hydroperoxide glutathione peroxidase
Oleoleic acid
OMomental adipose tissue
Palmpalmitic acid
PBDEsdiphenyl ethers
PDXprotectin DX
PGE2prostaglandin E2
PGF2αprostaglandin F2α
POpathological obesity
POPsorganic pollutants
PPARperoxisome proliferator-activated receptors
PUFAspolyunsaturated fatty acids
ROSreactive oxygen species
SATsubcutaneous adipose tissue
Sirt1sirtuin 1
Sp1transcription factor specificity protein 1
SREBP-1csterol regulatory element binding protein 1C
T2DMtype 2 diabetes
TNF-αtumor necrosis factor-α
TonEBPtonicity-responsive enhancer-binding protein
UPRunfolded protein response
VATvisceral adipose tissue
WISP2inducible-signaling pathway protein 2
ZNF423zinc finger protein 423
β3-ARbeta-3 adrenergic receptor
MSCsmesenchymal stem cells
Ap2adipocyte protein 2
CYPcytochrome P450
ALAalpha-lipoic acid

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution 3.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite and reference

Link to this chapter Copy to clipboard

Cite this chapter Copy to clipboard

Haya Al-Sulaiti, Alexander S. Dömling and Mohamed A. Elrayess (August 28th 2019). Mediators of Impaired Adipogenesis in Obesity-Associated Insulin Resistance and T2DM, Adipose Tissue - An Update, Leszek Szablewski, IntechOpen, DOI: 10.5772/intechopen.88746. Available from:

chapter statistics

84total chapter downloads

More statistics for editors and authors

Login to your personal dashboard for more detailed statistics on your publications.

Access personal reporting

Related Content

This Book

Next chapter

Introductory Chapter: Adipose Tissue

By Leszek Szablewski

Related Book

First chapter

Introductory Chapter: Types of Adipose Tissue

By Leszek Szablewski

We are IntechOpen, the world's leading publisher of Open Access books. Built by scientists, for scientists. Our readership spans scientists, professors, researchers, librarians, and students, as well as business professionals. We share our knowledge and peer-reveiwed research papers with libraries, scientific and engineering societies, and also work with corporate R&D departments and government entities.

More About Us